Regular
NAV (25-Jul-24)
Returns (Since Inception)
Fund Overview
Fund Size
₹34 Cr
Expense Ratio
1.09%
ISIN
INF277KA1BD0
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
26 Apr 2024
About this fund
As of 25-Jul-24, it has a Net Asset Value (NAV) of ₹11.10, Assets Under Management (AUM) of 34.00 Crores, and an expense ratio of 1.09%.
- Tata Nifty MidSmall Healthcare Index Fund Regular Growth has given a CAGR return of 10.96% since inception.
- The fund's asset allocation comprises around 98.70% in equities, 0.00% in debts, and 1.30% in cash & cash equivalents.
- You can start investing in Tata Nifty MidSmall Healthcare Index Fund Regular Growth with a SIP of ₹1000 or a Lumpsum investment of ₹5000.
Performance against Category Average
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
Since Inception
+10.96%
— (Cat Avg.)
Portfolio Summaryas of 30th June 2024
| Equity | ₹33.56 Cr | 98.70% |
| Others | ₹0.44 Cr | 1.30% |
Top Holdings
All Holdings
Equity
Debt & Others
| Name | Type  | Amount | Holdings |
|---|---|---|---|
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹6.94 Cr | 14.91% |
| Lupin Ltd | Equity | ₹3.91 Cr | 8.40% |
| Aurobindo Pharma Ltd | Equity | ₹3.39 Cr | 7.29% |
| Alkem Laboratories Ltd | Equity | ₹2.5 Cr | 5.38% |
| Fortis Healthcare Ltd | Equity | ₹2.47 Cr | 5.31% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹1.84 Cr | 3.95% |
| Laurus Labs Ltd | Equity | ₹1.67 Cr | 3.58% |
| Biocon Ltd | Equity | ₹1.56 Cr | 3.35% |
| Mankind Pharma Ltd | Equity | ₹1.53 Cr | 3.29% |
| Ipca Laboratories Ltd | Equity | ₹1.52 Cr | 3.26% |
| Abbott India Ltd | Equity | ₹1.47 Cr | 3.15% |
| Syngene International Ltd | Equity | ₹1.28 Cr | 2.76% |
| Gland Pharma Ltd | Equity | ₹1.26 Cr | 2.71% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹1.25 Cr | 2.69% |
| Global Health Ltd | Equity | ₹1.19 Cr | 2.56% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹1.08 Cr | 2.31% |
| Natco Pharma Ltd | Equity | ₹1.06 Cr | 2.27% |
| Dr. Lal PathLabs Ltd | Equity | ₹1.02 Cr | 2.19% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹1.02 Cr | 2.18% |
| Ajanta Pharma Ltd | Equity | ₹1 Cr | 2.14% |
| Piramal Pharma Ltd | Equity | ₹0.96 Cr | 2.05% |
| Poly Medicure Ltd | Equity | ₹0.87 Cr | 1.87% |
| Suven Pharmaceuticals Ltd | Equity | ₹0.82 Cr | 1.76% |
| Narayana Hrudayalaya Ltd | Equity | ₹0.81 Cr | 1.74% |
| Granules India Ltd | Equity | ₹0.67 Cr | 1.44% |
| Rainbow Childrens Medicare Ltd | Equity | ₹0.62 Cr | 1.33% |
| Sanofi India Ltd | Equity | ₹0.58 Cr | 1.25% |
| Metropolis Healthcare Ltd | Equity | ₹0.51 Cr | 1.09% |
| Alembic Pharmaceuticals Ltd | Equity | ₹0.48 Cr | 1.04% |
| Cash / Net Current Asset | Cash | ₹0.45 Cr | 0.97% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹0.4 Cr | 0.85% |
| Sanofi Consumer Healthcare India Ltd ^ | Equity - Future | ₹0.28 Cr | 0.60% |
| A) Repo | Cash - Repurchase Agreement | ₹0.15 Cr | 0.33% |
Allocation By Market Cap (Equity)
Large Cap Stocks
3.29%
Mid Cap Stocks
66.65%
Small Cap Stocks
28.16%
Other Allocation
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹45.68 Cr | 98.10% |
Risk & Performance Ratios
Standard Deviation
This fund
--
Cat. avg.
--
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
--
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
--
Higher the better
Fund Managers
Kapil Menon
Since April 2024
Additional Scheme Detailsas of 30th June 2024
ISIN | INF277KA1BD0 | Expense Ratio | 1.09% | Exit Load | No Charges | Fund Size | ₹34 Cr | Age | 26 Apr 2024 | Lumpsum Minimum | ₹5,000 | Fund Status | Open Ended Investment Company | Benchmark | Nifty MidSmall Healthcare Index (TRI) |
Investment Objective
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Tax Treatment
Withdrawal within 1 year
Flat 15% tax on realised gains (STCG - short term capital gains)
Withdrawal after 1 year
10% tax on realised gains above Rs. 1 lakh per financial year (LTCG - long term capital gains)
Note: Mutual funds are subject to capital gains taxation with surcharge and cess, based on prevailing income tax rules and investor income. Taxation applies to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Similar Index Funds Funds
| Fund name | Expense Ratio | Exit Load | Fund size | 1Y  |
|---|---|---|---|---|
| ICICI Prudential Nifty Midcap 150 Index Fund Direct Growth Very High Risk | 0.3% | 0.0% | ₹494.41 Cr | 52.5% |
| ICICI Prudential Nifty Midcap 150 Index Fund Regular Growth Very High Risk | 0.9% | 0.0% | ₹494.41 Cr | 51.5% |
| ICICI Prudential Nifty 200 Momentum 30 Index Fund Regular Growth Very High Risk | 1.0% | 0.0% | ₹264.53 Cr | 61.9% |
| SBI Nifty Midcap 150 Index Fund Regular Growth Very High Risk | 1.0% | 0.0% | ₹517.61 Cr | 51.8% |
| DSP Nifty 50 Equal Weight Index Fund Regular Growth Very High Risk | 1.0% | 0.0% | ₹1558.99 Cr | 35.3% |
| SBI Nifty Smallcap 250 Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹876.68 Cr | 57.0% |
| SBI Nifty Midcap 150 Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹517.61 Cr | 52.7% |
| ICICI Prudential Nifty 200 Momentum 30 Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹264.53 Cr | 62.9% |
| DSP Nifty 50 Equal Weight Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹1558.99 Cr | 36.0% |
| SBI Nifty Smallcap 250 Index Fund Regular Growth Very High Risk | 1.0% | 0.0% | ₹876.68 Cr | 56.0% |
Risk Level
Your principal amount will be at Very High Risk
Unlock Expert Insights!
Related Articles
Still got questions?
We're here to help.
What is the current NAV of Tata Nifty MidSmall Healthcare Index Fund Regular Growth?
What is the portfolio composition of Tata Nifty MidSmall Healthcare Index Fund Regular Growth?
Who manages the Tata Nifty MidSmall Healthcare Index Fund Regular Growth?
- Kapil Menon
Dezerv Investments Private Limited is a Portfolio Manager with SEBI Registration no. INP000007377 and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.
Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.